Pharma BD Deal Intelligence
A four-year exclusive base-editing research pact where Pfizer paid $300M upfront for opt-in rights across liver, muscle, and CNS rare disease targets. Pfizer exercised its liver-target opt-in in December 2025, though Beam still retains a co-commercialization option and undisclosed milestone/fee terms leave the deal's ultimate value unresolved.
Beam Therapeutics inks $300 million gene-editing collaboration with Pfizer for exclusive four-year research partnership in rare diseases.
Pfizer buys into next-generation gene editing in $300 million deal with Beam Therapeutics combining mRNA/LNP delivery technologies.
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate — Pfizer opted to advance an unnamed liver disease program; Beam…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Pfizer entered a four-year exclusive multi-target research collaboration with Beam Therapeutics (announced Jan 10, 2022) for in vivo base editing programs targeting rare genetic diseases of the liver, muscle, and central nervous system. Pfizer paid $300M upfront, with up to $1.05B in milestone payments (total consideration up to $1.35B) contingent on Pfizer exercising opt-in licenses across the three targets. UPDATE: in December 2025, at the completion of the four-year research period, Pfizer opted in to an exclusive, worldwide license for one liver-targeted base editing development candidate (built on Beam's proprietary liver-targeting LNP); Pfizer assumes all development, manufacturing, regulatory and commercialization responsibility. Beam remains eligible for development, regulatory and commercial milestone payments and retains a right to opt in, at the end of Phase 1/2, to a global co-development and co-commercialization agreement under which Beam and Pfizer would share net profits and costs 35%/65% (Beam/Pfizer). Beam disclosed the opt-in in its Q4/FY2025 results (Feb 24, 2026). Opt-in fee and specific milestone amounts were not disclosed.
$29.0B US Rare Disease Therapeutics Market
Rare genetic diseases collectively affect approximately 25-30 million Americans across more than 7,000 distinct conditions. The Pfizer-Beam collaboration targets rare genetic diseases of the liver, muscle, and central nervous system using base editing technology, which enables precise single-nucleotide changes without double-strand DNA breaks.
Base editing represents a next-generation precision genetic medicine approach. Unlike traditional CRISPR-Cas9 which creates double-stranded breaks, base editors chemically convert one DNA base to another with higher precision and fewer off-target effects. Key competitors include Verve Therapeutics (cardiovascular), Beam Therapeutics (hematology), and Prime Medicine (prime editing).
$29.0B US Rare Disease Therapeutics Market
This deal record represents the same Pfizer-Beam base editing research collaboration targeting rare genetic diseases of the liver, muscle, and CNS. Beam received $300M upfront with up to $1.05B in milestones. Beam retains option to co-develop/co-commercialize one program at 35/65 split.
Base editing represents a next-generation precision genetic medicine approach. Unlike traditional CRISPR-Cas9 which creates double-stranded breaks, base editors chemically convert one DNA base to another with higher precision and fewer off-target effects. Key competitors include Verve Therapeutics (cardiovascular), Beam Therapeutics (hematology), and Prime Medicine (prime editing).
Pfizer paid $300M upfront for in vivo base editing programs in liver, muscle, and CNS diseases.
Beam received $300M upfront for exclusive 4-year collaboration on three in vivo base editing targets.
At the completion of the four-year research collaboration, Pfizer exercised its opt-in for an exclusive, worldwide license to one liver-targeted in vivo base editing development candidate. Pfizer assumes all development, manufacturing, regulatory and commercialization responsibility; Beam is eligible for development/regulatory/commercial milestones and retains a Phase 1/2 co-dev/co-commercialization opt-in at a 35%/65% (Beam/Pfizer) split. Disclosed by Beam Feb 24, 2026.
Base editing programs advancing through preclinical development. Novel gene editing modality.
Programs in preclinical development for rare genetic diseases of liver, muscle, and CNS.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Beam Therapeutics Inc. (this deal) | 2022 | $1.4B | 63 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Gene Therapy deals